NCT05394350 2024-11-08
MK-1088-002
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT05430555 2024-02-07
IMAG1NE
T-knife GmbH
Phase 1/2 Terminated
NCT05010525 2023-03-17
REACH
Antengene Corporation
Phase 1/2 Terminated
NCT02880371 2022-06-16
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01433991 2021-06-08
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
Eisai Inc.
Phase 1/2 Terminated
NCT02253992 2020-10-05
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03065023 2019-07-30
MK-4621-001
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00546247 2015-10-12
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00550017 2015-10-12
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
Bristol-Myers Squibb
Phase 1/2 Terminated